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Abstract
Background: Dengue virus infected patients have high plasminogen activator inhibitor type I (P A I-l) plasma 
concentrations. W hether the insertion/deletion (4G/5G) polymorphism in the p rom oto r region o f the PAI-l gene 
is associated w ith increased PAI-l plasma concentrations and w ith death from dengue is unknown. W e, therefore, 
investigated the relationship between the 4G/5G polymorphism and PAI-l plasma concentrations in dengue 
patients and risk o f death from dengue.
Methods: A  tota l o f l94 patients admitted to  the Dr. Kariadi Hospital in Semarang, Indonesia, w ith clinical 
suspected severe dengue virus infection were enrolled. Blood samples were obtained on day o f admission, days
l, 2 and 7 after admission and at a l -month follow-up visit. Plasma concentrations o f PAI-l were measured using
a sandwich ELISA kit. The PAI-l 4G/5G polymorphism was typed by allele-specific PCR analysis.
Results: Concentrations o f PAI-l on admission and peak values o f PAI-l during admission were higher than the
values measured in healthy controls. Survival was significantly worse in patients w ith PAI-l concentrations in the
highest te rtile  (at admission: OR 4.7 [95% CI 0.9-23.8], peak value during admission: OR 6.3 [95%CI l .3-30.8]).
No association was found between the PAI-l 4G/5G polymorphism, and PAI-l plasma concentrations, dengue
disease severity and m ortality from  dengue.
Conclusion: These data suggest that the 4G/5G polymorphism has no significant influence on PAI-l
concentrations in dengue virus infected patients and is not associated w ith the risk o f death from dengue. O ther
factors contributing to  the variability o f PAI-l plasma concentrations in patients w ith dengue need to  be explored.
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Background
Dengue is the most prevalent viral disease transmitted by 
arthropod vectors worldwide [1]. An estimated 50-100 
million cases of dengue fever and 500.000 cases of dengue 
haemorrhagic fever resulting in around 24.000 deaths 
occur annually depending on epidemic activity [1,2]. At 
present, almost 30% of the world population is at risk for 
dengue virus infection and it is expected that this number 
will increase substantially as transmission spreads to 
other yet unaffected geographic regions [3]. The viruses 
are transmitted to humans through infected mosquitoes, 
and may induce clinical manifestations ranging from a 
mild, uncomplicated febrile illness to the more severe 
dengue haemorrhagic fever and dengue shock syndrome. 
Increased vascular permeability is thought to be central in 
the pathogenesis of dengue haemorrhagic fever and den­
gue shock syndrome, since it results in the loss of plasma 
from the vascular compartment, which may give rise to 
shock in severe cases. Bleeding manifestations are 
believed to result from thrombocytopenia and thrombo- 
cytopathia, but increasing evidence suggests an important 
role for other abnormalities in the coagulation and fibri­
nolytic systems [4].
Nearly all patients suffering from dengue haemorrhagic 
fever show some evidence of a deranged coagulation sys­
tem, but coagulation abnormalities are most marked in 
dengue shock syndrome patients [5]. The activity of the 
fibrinolytic system is amongst others regulated by plas­
minogen activator inhibitor type I (PAI-1), of which levels 
may greatly increase during acute phase reactions. Indeed, 
levels of PAI-1 are high in particular in dengue shock syn­
drome patients with an adverse clinical outcome [6,7]. A 
single base pair insertion/deletion (4G/5G) polymor­
phism in the prom otor region of the PAI-1 gene has been 
associated with increased plasma concentrations of PAI-1 
and with the development of shock and death after infec­
tion with Neisseria meningitides [8,9]. We therefore 
investigated whether in dengue virus infected patients 
increased PAI-1 levels are associated with a greater risk of 
death from dengue and whether the 4G/4G genotype con­
tributes to these higher levels.
Methods
Patients were selected from two observational studies con­
ducted in the Dr. Kariadi Hospital in Semarang, Indone­
sia. In the first study, performed from 1996 to 1997 at the 
paediatric intensive care unit, a total of 50 patients with a 
clinical diagnosis of suspected dengue shock syndrome 
were studied. Blood samples were obtained from these 
patients on day of admission and on days 1, 2 and 7 after 
admission. The study protocol and the results of the meas­
urement of PAI-1 plasma levels have been described pre­
viously [6]. The second study was performed from 2001 to 
2003 at the paediatric intensive care unit and the paediat­
ric ward. Patients, aged 3 to 14 years, admitted to the hos­
pital with a clinical diagnosis of suspected dengue shock 
syndrome or with a clinical diagnosis of suspected dengue 
haemorrhagic fever were included. Demographic data, 
medical history, physical examination findings and subse­
quent progress for each patient were recorded on a stand­
ard data form. Blood samples were obtained on day of 
admission, days 1, 2 and 7 after admission and at a 1- 
m onth follow-up visit. A formal classification, according 
to WHO criteria [2], using all available clinical and labo­
ratory data, was done after completion of both studies. If 
dengue virus infected patients did not meet the criteria for 
dengue haemorrhagic fever or dengue shock syndrome, 
they were considered to suffer from dengue fever. The con­
trols were healthy school-aged children who had no his­
tory of dengue haemorrhagic fever or dengue shock 
syndrome and originated from the same geographical area 
as the cases.
All blood samples were centrifuged within 1-2 hours after 
retrieval at 15°C for 20 minutes at 1600*g. Plasma was 
separated, stored at -80°C and assayed batch-wise in the 
Netherlands after transportation on dry ice. Since coagu­
lation test results are affected by poor sample quality, only 
test results of samples with no visible haemolysis or clot 
formation were included in this analysis. Plasma concen­
trations of PAI-1 were measured using two separate assays. 
A sandwich ELISA kit that has been described by de Boer 
et al [10], was used in the 1996-1997 study. In the second 
study a commercially available sandwich ELISA kit (Imu- 
lyse, Biopool, Sweden) was used. Genomic DNA from 
patients was prepared either from EDTA whole blood by 
means of a salting out m ethod as described elsewhere or 
in case only plasma samples were available with use of the 
Invisorb® Spin Cell Mini Kit (Invitek GmbH, Berlin, Ger­
many) [11]. The insertion/deletion (4G/5G) polymor­
phism in the prom otor region of the PAI-1 gene was typed 
by allele-specific PCR and RFLP analysis [11]. The ethics 
committee of the Dr. Kariadi Hospital approved all clini­
cal and laboratory aspects of both studies. Blood samples 
were taken from patients and controls provided that a par­
ent or legal guardian gave informed consent.
Paired blood samples from both studies were tested for 
serologic evidence of acute dengue infection. A commer­
cially available capture and indirect ELISA (Focus Tech­
nologies, Cypress, Calif., USA) was used for the detection 
of dengue virus specific IgM and IgG antibodies respec­
tively. This was performed according to the procedures 
described by the manufacturer [12]. For some patients, a 
definitive serodiagnosis was not possible because no con­
valescent sample was obtained. Detection of dengue anti­
gen and RNA was attempted in these cases using a dot blot 
immunoassay and a dengue serotype specific revere tran­
scriptase PCR respectively [13]. Patients with serologic
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T a b le  1: C lin ic a l c h a ra c te r is tic s  and la b o ra to ry  find in gs
Characteristic
Age, median (IQR), years 6 (4 -10)
Male sex, n (%) 92 (47)
D uration o f symptoms, median (range), days 4 (1 -7)
Systolic blood pressure, median (IQR), mmHg 90 (80-100)
Pulse pressure <20 mmHg, n (%) 22 (1 1)
Spontaneous bleeding, n (%) 1 18 (62)
Haem atocrit, median (IQR), % 41 (36-45)
Platelet count, median (IQR), cells * l0 3/m m 3 58 (37-85)
° IQR denotes 25th and 75th in terquartile  range, n denotes number 
o f patients.
evidence of acute dengue infection, a positive dot blot 
and/or positive PCR were considered to have confirmed 
dengue virus infection. Those with definite negative serol­
ogy and/or a well-substantiated alternative clinical diag­
nosis were classified as not dengue. In the absence of a 
well-substantiated alternative clinical diagnosis and with 
inconclusive serology patients were classified as indeter­
minate.
Categorical data are expressed as numbers and frequen­
cies, and were compared by means of x2 analysis. Contin­
uous data are expressed as medians with corresponding 
interquartile ranges and were compared by means of the 
Kruskal Wallis test. Since PAI-1 plasma levels were meas­
ured using two different assays, the nonparametric regres­
sion procedure of Passing and Bablok was used to 
compare these two methods and to validate recalculation 
of one of the datasets to pool the data [14]. For this pur­
pose, 39 samples were analysed with both assays. The 
Passing and Bablok regression equation resulting from 
this comparison is given in the Results section, together 
with the 95% confidence intervals for the estimates of 
slope and intercept. PAI-1 plasma levels obtained from 
the 1996-1997 cohort were converted using the regres­
sion equation. We subsequently divided PAI-1 plasma lev­
els on admission and peak PAI-1 plasma levels during 
admission into tertiles of similar size. Odds ratios and the 
corresponding 95% confidence intervals (95% CI) were 
estimated by cross-tabulation using the lowest tertile as 
reference category. To determine the association between
PAI-1 concentration and mortality independent of age, 
sex, year project and plasminogen activator inhhibitor-1 
polymorphism, we used logistic regression analyses. A P- 
value < 0.05 was considered to indicate statistical signifi­
cance. Analyses were performed using SPSS 11.0.1. 
Method comparison was performed using Analyse-it Clin­
ical Laboratory statistics module version 1.62 for Micro­
soft Excel.
Results
Of 233 enrolled patients with suspected dengue haemor- 
rhagic fever or dengue shock syndrome admitted to the 
paediatric intensive care unit and the paediatric ward of 
the Dr. Kariadi Hospital, 202 (87%) were confirmed to 
have acute dengue, 3 (1%) were categorised as definitely 
not dengue and 28 (12%) as indeterminate. When a for­
mal classification using the criteria set by the WHO was 
performed, 106 (52%) were classified as having dengue 
shock syndrome, 76 (38%) as having dengue haemor- 
rhagic fever and 20 (10%) as having dengue fever. Nine­
teen of 202 patients with confirmed dengue (9%) died 
during follow up.
Genomic DNA was obtained from 194 patients. The 
remaining patients could not be typed because of insuffi­
cient volume of blood left or low yield of DNA. Clinical 
features and basic laboratory investigations on admission 
of the 194 patients are summarised in Table 1. The num ­
bers of 4G/4G, 4G/5G and 5G/5G PAI-1 genotypes 
among patients in relation to mortality are summarised in 
Table 2. Of 192 control samples tested, 45 patients (23%) 
were 4G/4G homozygous, 83 (43%) were 4G/5G hetero­
zygous, and 64 (33%) were 5G/5G homozygous. The fre­
quencies of the PAI-1 promoter genotypes 4G/4G, 4G/5G, 
and 5G/5G did not differ significantly between the 1996­
1997 project, the 2001-2003 project and the control 
group (P = 0.520). The proportion of deaths among 
patients with the 4G/4G, 4G/5G and 5G/5G genotype did 
not differ significantly (1996-1997 project: P = 0.979; 
2001-2003 project: P = 0.986; two projects combined: P 
= 0.781). The genotype frequencies among patients with 
respect to final clinical diagnosis according to the criteria 
set by the WHO are summarised in Table 3. Results indi-
T a b le  2: C lin ic a l o u tc o m e  o f  de ngue  v iru s  in fe c te d  p a tie n ts  c lass ified  by  PAI-1 g e n o typ e
1996-1997 2001-2003
Genotype All patients Survivors Non-survivors A ll patients Survivors Non-survivors
G4/G4 8 (18%) 6 (14%) 2 (5%) 33 (22%) 32 (21%) 1 (1%)
G4/G5 l5  (34%) l l  (25%) 4 (9%) 62 (41%) 60 (40%) 2 (1%)
G5/G5 2 l (48%) 15 (34%) 6 (14%) 55 (37%) 53 (35%) 2 (1%)
Total 44 (100%) 32 (73%) l2  (27%) 150 (100%) l45  (97%) 5 (3%)
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T a b le  3: D eng ue  disease s e v e r ity  and PAI-1 g e n o typ e
Genotype DF DHF DSS
G4/G4 6 (3%) 13 (7%) 22 (1 1%)
G4/G5 6 (3%) 35 (18%) 36 (19%)
G5/G5 8 (4%) 27 (14%) 41 (21%)
Total 20 (10%) 75 (39%) 99 (51%)
cate that the PAI-1 promoter genotypes are not associated 
with dengue disease severity (P = 0.508).
PAI-1 plasma levels were measured in 124 patients from 
whom sufficient frozen plasma samples was available 
with the use of two separate ELISA's. Thirty-nine random 
plasma samples were used for the comparison of the two 
assays. PAI-1 level measurements are known to be 
dependent on the assay employed, since not all antibod­
ies used have the same specificity with respect to the vari­
ous molecular forms of PAI-1 in blood (active PAI-1, PAI- 
1 complexed with vitronectin, inactive or latent PAI-1 and 
PAI-1 complexed with its target proteases tissue-type and 
urokinase-type plasminogen activator) [15]. Passing & 
Bablok regression analysis (Figure 1), however, clearly
showed that the two assays employed in this study have a 
straightforward linear relationship between their out­
comes. This allowed us to convert the PAI-1 levels meas­
ured in the 1996-1997 cohort to levels that would have 
been obtained with the assay used in the second cohort, 
using the Passing and Bablok regression equation (an 
intercept of -7.42 ng/ml (95% CI, -16.39 to -3.24 ng/ml) 
and slope of 0.35 (95% CI, 0.30 to 0.42)). Concentrations 
of PAI-1 on admission (71 ng/ml [42-118]) and peak val­
ues during admission (96 ng/ml [64-199]) were higher 
than the concentrations measured in the healthy control 
group (30-60 ng/ml). Patients included in the 2001­
2003 project and diagnosed with DSS had higher PAI-1 
plasma levels on admission (P = 0.002) and during 
admission (P < 0.001) than those diagnosed with DF or 
DHF (Table 4). However, no statistical significant differ­
ence was present between patients with different dengue 
disease severities when both projects were combined 
(PAI-1 plasma levels on admission: P = 0.212 and during 
admission: P = 0.089). Survival was significantly worse in 
patients with PAI-1 concentrations in the highest tertile 
(Table 5). As shown by multiple logistic regression analy­
sis, the odds ratio for the risk of death -  adjusted for age, 
sex, year project and plasminogen activator inhibitor-1 
genotype -  of PAI-1 levels at admission in the highest ter-
i ;  1000-
<Q.
i ;  1 0 0 0 -
<Q.
PAI-1 polymorphism PAI-1 polymorphism
A B
1500 1500
500 500
0 0
G4 G5 G4 G5
F ig u re2
R e la tion  b e tw e e n  PAI-1 p lasm a c o n c e n tra tio n s  and PAI-1 g e n o typ e  in dengue  v iru s  in fe c te d  p a tie n ts . Box-and- 
whisker plots o f PAI-1 plasma concentrations on admission (A.) and peak values during admission (B.). The central line in the 
box plot represents the median, the boxed areas represent the interquartile ranges. Whiskers at the ends o f the box show the 
distance from the end o f the box to  the largest and smallest observed values that are less than l .5  box lengths from either end 
o f the box.
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P lasm inogen activator inhibitor-1  
de Boer [10]
F ig u re !
C o m p a riso n  o f  tw o  P A I- ! assays. Comparison o f PAI-1 
plasma levels obtained by a Biopool assay and an assay previ­
ously described by de Boer and colleagues [10]). The Passing 
& Bablok regression equation is: y = 0,3505x - 7,4227 ng/ml; 
n = 39. Solid line, regression line; dashed lines, 95% CI fo r the 
regression line.
tile was 7.57 (95%CI, 1.16-49.30). The adjusted odds 
ratio for the risk of death of peak PAI-1 levels during 
admission in the highest tertile was 7.41 (95%CI, 1.30­
42.26). Figure 2 illustrates the relation between PAI-1 
plasma concentrations and the PAI-1 genotypes. Differ­
ences were not statistically significant (values at admis­
sion: P = 0.919; peak values during admission: P = 0.470).
Discussion
This study was undertaken to investigate the relationship 
between PAI-1 plasma concentrations and clinical out­
come of dengue virus infections, and to establish whether 
PAI-1 plasma concentrations in dengue virus infected 
individuals are associated with the 4G/5G prom otor pol­
ymorphism in the PAI-1 gene. We and others have previ­
ously found increased PAI-1 plasma concentrations in 
patients with severe dengue in  particular in  those with a 
poor clinical outcome [5,7]. Since a genetic predisposition 
to produce high PAI-1 plasma concentrations appears to 
be associated with poor clinical outcome in Neisseria 
meningitides infections [8,9], we hypothesised that den­
gue virus infected individuals carrying the 4G/4G geno­
type have higher PAI-1 plasma concentrations and are 
therefore at increased risk of death. Consistent with previ­
ous studies, we found increased PAI-1 concentrations in
dengue virus infected individuals. However, PAI-1 plasma 
concentrations were not related to dengue disease sever­
ity, bu t were significantly associated with death from den­
gue. No significant association between PAI-1 plasma 
concentrations and carriage of the 4G/4G genotype was 
observed. The frequencies of the three genotypes between 
survivors and non-survivors, and between patients with 
different disease severities were no t different. These find­
ings suggest that increased PAI-1 plasma concentrations, 
and dengue disease severity and mortality are no t depend­
ent on the 4G polymorphism in the PAI-1 gene in this 
population.
An increased risk of death in dengue virus infected 
patients with high PAI-1 plasma concentrations adds to 
findings of PAI-1 levels being able to predict lethality in 
patients with bacterial sepsis in a very sensitive way [16­
20]. One of the primary roles of PAI-1 in vivo is to inhibit 
tissue-type plasminogen activator, the major proteolytic 
activator of plasminogen [21,22]. By inhibiting fibrino­
lytic activity, increased PAI-1 concentrations may contrib­
ute to a procoagulant state leading to an increased 
deposition of fibrin and formation of microthrombi with 
subsequent multiorgan failure and death. A variety of 
cells, including endothelial cells, hepatocytes and plate­
lets, synthesize and secrete PAI-1 in response to inflam­
matory stimuli such as interleukin-1 and tum our necrosis 
factor [10,22-24]. The release of these inflammatory 
mediators by monocytes and T lymphocytes activated by 
dengue virus may well contribute to the over-production 
of this inhibitor of fibrinolysis [25-27]. Dawson and col­
leagues showed that the common insertion/deletion (4G/ 
5G) polymorphism in the prom otor region of the PAI-1 
gene affects the response of the gene to acute phase stim­
uli [23]. The 4G allele produced six times more mRNA 
than the 5G allele in response to interleukin-1 [23]. Eriks­
son and colleagues, however, were unable to reproduce 
these findings and based on their study results they con­
cluded that the insertion/deletion (4G/5G) polymor­
phism is no t related to an allele-specific response to 
interleukin-1 [28]. Instead, they found that the insertion/ 
deletion (4G/5G) polymorphism influences basal PAI-1 
transcription only [28].
Apparently other underlying mechanisms not related to 
the 4G/5G polymorphism must be involved in the 
increase in PAI-1 levels found in dengue virus infected 
individuals. This might include clearance impairment 
rather than or in addition to stimulation of synthesis. It is 
interesting to note that PAI-1 is cleared from the circula­
tion by the liver [29]. Indeed in patients with severe liver 
disease, PAI-1 has been shown to be increased as a result 
of a decrease in hepatic clearance [30,31]. Since hepatic 
dysfunction is a relatively common finding in severe den­
gue virus infections, it is possible that a less efficient clear­
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T a b le  4: R e la tio n  b e tw e e n  PAI-1 p la sm a  levels and disease s e v e r ity 0
Project PAI-1
(ng/ml)
DF
Median (IQR)
DHF
Median (IQR)
DSS
Median (IQR)
1996-1997^ Admission _ - 56.7 (33.0-130.2)
Peak values - - 91.6 (37.7-343.6)
2001-2003 Admission 77.0 (69.0-99.0) 60.0 (42.3-82.5) 107.0 (52.0-670.0)
Peak values 82.0 (69.0-129.0) 78 (59.3-118.3) 264.0 (1 17.0-844.0)
Total Admission 77.0 (69.0-99.0) 60.0 (42.3-82.5) 87.0 (35.0-180.8)
Peak values 82.0 (69.0-129.0) 78 (59.3-118.3) 130.7 (53.7-531.1)
° IQR denotes 25th and 75th in terquartile  range.
^  O nly DSS patients w ere included in the 1996 project.
ance contributes to increased PAI-1 levels in dengue virus 
infected individuals [32-34]. Previous studies investigated 
factors that could potentially influence PAI-1 levels, 
including environmental factors, metabolic determinants, 
ethnicity and a variety of other polymorphisms within the 
PAI-1 gene [35-38]. It remains unclear whether and to 
what extent these factors contribute to the variability in 
PAI-1 levels in dengue virus infected individuals. Previ­
ously studied individuals were either healthy, were 
patients with coronary artery disease, or were patients 
with diabetes mellitus. Clearly these study populations 
cannot be compared to patients suffering from a severe 
infectious disease that is characterised by an overwhelm­
ing inflammatory response.
Several potential limitations of the present study should 
be noted. The 1996-1997 cohort was characterized with a 
high mortality rate of 27%. Although the exact reason for 
this high mortality remains to be determined, it is likely 
that it results from a combination of factors. Our study 
was performed in a Tertiary Hospital that serves a large 
part of Middle-Java. Patients may travel long distances to 
be treated in this hospital and it could well be that they are 
presented late in the course of disease. Initial fluid resus­
citation according to WHO guidelines is generally insuffi­
cient in these cases and patients usually end up in 
profound shock. Despite admission at the Pediatric Inten­
T a b le  5: M o r ta l i ty  r is k  fo r  p lasm inog en  a c tiva to r-1  p lasm a  leve ls .*
PAI-1 ng/ml N um ber o f patients N um ber o f deaths OR (95% CI) ORadj (95% CI)°
Value at admission <50 41 2 1 1
50-94 40 3 1.6 (0.3-10.0) 3.3 (0.4-25.0)
>94 41 8 4.7 (0.9-23.8) 7.6 (1.2-49.3)
Maximum value during 
admission
<72 41 2 1 1
72-151 42 3 1.5 (0.2-9.5) 2.1 (0.2-18.2)
>151 41 10 6.3 (1.3-30.8) 7.4 (1.3-42.3)
*  CI, denotes confidence interval; OR, denotes odds ratio; ORadj, denotes adjusted odds ra tio
° Risk o f death adjusted fo r age, sex, year p ro jec t and plasminogen activator in h h ib ito r-1 polymorphism. Lowest te rtile  was used as reference 
category.
sive Care Unit mortality rate is high. In addition, the 
1996-1997 rainy season was characterised by high num ­
bers of patients admitted to hospitals because of DHF/ 
DSS and high num ber of non-survivors. It is believed that 
an unusually virulent virus circulated that year although 
microbiological sampling could not be performed at that 
time because of limited resources.
Study size is an im portant issue in the establishment of an 
association between the insertion/deletion (4G/5G) poly­
morphism in the PAI-1 gene and clinical outcome. Her­
mans and colleagues previously found an association 
between the homozygous 4G deletion polymorphism and 
mortality from Neisseria meningitides infection among 
129 patients from two different cohort groups [8]. This 
association was also observed when the largest of the two 
cohort groups was studied separately, bu t was no t seen in 
the smallest group in which only 37 patients were 
included. In order to obtain a sufficient num ber of 
patients, we therefore decided to combine the results of 
two different projects. This decision was based on the fact 
that these two projects included patients with the same 
ethnic background, used similar trial procedures and 
applied uniform diagnostic and clinical management pro­
cedures. Although mortality rates between the 1996-1997 
cohort and the 2001-2003 cohort differed considerably, 
one must realise that in the 1996-1997 cohort only DSS
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patients were included. In the 2001-2003 cohort also 
included patients who had no evidence of circulatory fail­
ure were included. Mortality rate among DSS patients 
included in the 2001-2003 cohort was 18%. Our findings 
of similar frequencies of the PAI-1 genotypes within the 
1996-1997 project and the 2001-2003 project supports 
our decision to combine both groups.
In conclusion, this study demonstrates that high PAI-1 
plasma levels are associated with an increased risk of 
death from dengue without the 4G/5G polymorphism in 
the prom otor of the gene for PAI-1 playing a role. Addi­
tional studies are needed to explore the possibility of 
other polymorphisms within the PAI-1 gene and factors, 
like ethnicity or environmental factors, contributing to 
the variability of PAI-1 plasma concentrations in patients 
with dengue.
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